Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013.
作者信息
Maitra Arundhati, Bhakta Sanjib
机构信息
Department of Biological Sciences, University of London, London, UK.
出版信息
Virulence. 2013 Aug 15;4(6):499-503. doi: 10.4161/viru.25397. Epub 2013 Jun 18.
Abstract
摘要
相似文献
1
Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013.
Virulence. 2013 Aug 15;4(6):499-503. doi: 10.4161/viru.25397. Epub 2013 Jun 18.
2
Could Killing Bacterial Subpopulations Hit Tuberculosis out of the Park?
J Med Chem. 2016 Jul 14;59(13):6025-6. doi: 10.1021/acs.jmedchem.6b00875. Epub 2016 Jun 20.
3
Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.
Nat Rev Microbiol. 2008 Jan;6(1):41-52. doi: 10.1038/nrmicro1816.
4
Overcoming the global crisis: "yes, we can", but also for TB ... ?
Eur J Immunol. 2009 Aug;39(8):2014-20. doi: 10.1002/eji.200939518.
5
The relevance of persisters in tuberculosis drug discovery.
Microbiology (Reading). 2019 May;165(5):492-499. doi: 10.1099/mic.0.000760. Epub 2019 Feb 18.
6
Tuberculosis drug resistance mutation database.
PLoS Med. 2009 Feb 10;6(2):e2. doi: 10.1371/journal.pmed.1000002.
7
Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
J Genet Genomics. 2017 Jan 20;44(1):21-37. doi: 10.1016/j.jgg.2016.10.002. Epub 2016 Oct 11.
8
Development of new anti-tuberculosis drug candidates.
Tohoku J Exp Med. 2010 Jun;221(2):97-106. doi: 10.1620/tjem.221.97.
9
Isoniazid activity is terminated by bacterial persistence.
J Infect Dis. 2007 Jun 15;195(12):1871-2; author reply 1872-3. doi: 10.1086/518046.
10
Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
Biomed Pharmacother. 2018 Jul;103:1733-1747. doi: 10.1016/j.biopha.2018.04.176.
引用本文的文献
1
Early diagnosis and effective treatment regimens are the keys to tackle antimicrobial resistance in tuberculosis (TB): A report from Euroscicon's international TB Summit 2016.
Virulence. 2017 Aug 18;8(6):1005-1024. doi: 10.1080/21505594.2016.1256536. Epub 2016 Nov 4.
2
Tackling tuberculosis: Insights from an international TB Summit in London.
Virulence. 2015;6(6):661-72. doi: 10.1080/21505594.2015.1060396. Epub 2015 Jul 7.
3
TB Summit 2014: prevention, diagnosis, and treatment of tuberculosis-a meeting report of a Euroscicon conference.
Virulence. 2014 Jul 1;5(5):638-44. doi: 10.4161/viru.29803. Epub 2014 Jul 8.
本文引用的文献
1
Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay.
BMJ Open. 2013 Jun 20;3(6):e002672. doi: 10.1136/bmjopen-2013-002672.
2
Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.
J Infect Dis. 2013 Jul 15;208(2):199-202. doi: 10.1093/infdis/jit152. Epub 2013 Apr 5.
3
Characterisation of ATP-dependent Mur ligases involved in the biogenesis of cell wall peptidoglycan in Mycobacterium tuberculosis.
PLoS One. 2013;8(3):e60143. doi: 10.1371/journal.pone.0060143. Epub 2013 Mar 21.
4
Mobile health to improve tuberculosis care and control: a call worth making.
Int J Tuberc Lung Dis. 2013 Jun;17(6):719-27. doi: 10.5588/ijtld.12.0638. Epub 2013 Mar 25.
5
Drug-resistant tuberculosis: time for visionary political leadership.
Lancet Infect Dis. 2013 Jun;13(6):529-39. doi: 10.1016/S1473-3099(13)70030-6. Epub 2013 Mar 24.
6
Tuberculosis biomarkers discovery: developments, needs, and challenges.
Lancet Infect Dis. 2013 Apr;13(4):362-72. doi: 10.1016/S1473-3099(13)70034-3. Epub 2013 Mar 24.
7
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.
Lancet Infect Dis. 2013 Apr;13(4):349-61. doi: 10.1016/S1473-3099(13)70008-2. Epub 2013 Mar 24.
8
Tuberculosis.
N Engl J Med. 2013 Feb 21;368(8):745-55. doi: 10.1056/NEJMra1200894.
9
Piperidinols that show anti-tubercular activity as inhibitors of arylamine N-acetyltransferase: an essential enzyme for mycobacterial survival inside macrophages.
PLoS One. 2012;7(12):e52790. doi: 10.1371/journal.pone.0052790. Epub 2012 Dec 28.
10
Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors.
Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11354-9. doi: 10.1073/pnas.1205735109. Epub 2012 Jun 25.
Zotero 插件